{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:00:58Z","timestamp":1787169658348,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Primary biliary cholangitis (PBC) is a progressive autoimmune cholestatic liver disease that primarily affects females more than males and may lead to end-stage liver disease. We studied baseline characteristics, and the biochemical and clinical response to ursodeoxycholic acid (UDCA), a first-line treatment option for patients with PBC, in a cohort of patients diagnosed with PBC from Saudi Arabia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A total of 30 patients meeting the diagnostic criteria of PBC who were being followed in the King Faisal Specialist Hospital and Research Centre in Riyadh, Saudi Arabia, between January 1, 2008, and December 31, 2017, were enrolled in the study. The patients with autoimmune hepatitis, primary sclerosing cholangitis, and overlap syndromes were excluded. The baseline characteristics of the patients were recorded. The response to UDCA treatment was assessed according to the Barcelona, Paris I, Paris II, and Toronto criteria, and clinical outcomes, and biochemical changes were ascertained.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The mean age was 46 years \u00b1 11.7 with a female gender predominance of 93% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 28). Pruritus was the predominant symptom reported by 90% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 27) of the patients. A total of 23 (77.7%) patients underwent liver biopsy and all of them showed histological features suggestive of PBC. Cirrhosis was documented in 30% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 9) of the patients at baseline. Overall, 86.7% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 26) of the patients were positive for antimitochondrial antibodies. The biochemical response rates to UDCA based on Paris I, Paris II, Barcelona, and Toronto criteria were 73.3, 40, 56.7, and 53.3%, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Over 10 years, 30 patients with PBC were diagnosed at a large referral center in Saudi Arabia. The response to UDCA treatment was inadequate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/sjg.sjg_445_21","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T04:20:37Z","timestamp":1645590037000},"page":"135-140","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of ursodeoxycholic acid for primary biliary cholangitis: Experience from a tertiary care centre in Saudi Arabia"],"prefix":"10.4103","volume":"29","author":[{"given":"Ahmed H","family":"AlWabel","sequence":"first","affiliation":[{"name":"Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musthafa","family":"Peedikayil","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulaiman","family":"AlNasser","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"AlHusaini","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othman","family":"AlHekail","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh A","family":"Alqahtani","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"},{"name":"Organ Transplant Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim H","family":"AlTraif","sequence":"additional","affiliation":[{"name":"Hepatology Division, Department of Hepatobiliary Sciences and Organ Transplant Center, King Abdulaziz Medical City, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamad","family":"AlAshgar","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"R1-20240829","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan","year":"2005","journal-title":"N Engl J Med"},{"key":"R2-20240829","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2152\/jmi.64.7","article-title":"Primary biliary cholangitis: Its pathological characteristics and immunopathological mechanisms","volume":"64","author":"Tsuneyama","year":"2017","journal-title":"J Med Invest"},{"key":"R3-20240829","doi-asserted-by":"crossref","first-page":"926","DOI":"10.4254\/wjh.v7.i7.926","article-title":"Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy","volume":"7","author":"Purohit","year":"2015","journal-title":"World J Hepatol"},{"key":"R4-20240829","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1056\/NEJM199611213352107","article-title":"Primary biliary cirrhosis","volume":"335","author":"Kaplan","year":"1996","journal-title":"N Engl J Med"},{"key":"R5-20240829","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(10)61965-4","article-title":"Primary biliary cirrhosis","volume":"377","author":"Selmi","year":"2011","journal-title":"Lancet"},{"issue":"7 Suppl","key":"R6-20240829","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.4103\/sjg.SJG_159_18","article-title":"The Saudi association for the study of liver diseases and transplantation clinical practice guidelines for management of autoimmune hepatitis","volume":"24","author":"Aljumah","year":"2018","journal-title":"Saudi J Gastroenterol"},{"key":"R7-20240829","doi-asserted-by":"crossref","first-page":"230","DOI":"10.5144\/0256-4947.1991.230","article-title":"Association of primary biliary cirrhosis and progressive systemic sclerosis in a Saudi patient","volume":"11","author":"Al-Dalaan","year":"1991","journal-title":"Ann Saudi Med"},{"key":"R8-20240829","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/gut.2003.023937","article-title":"Asymptomatic primary biliary cirrhosis: Clinical features, prognosis, and symptom progression in a large population based cohort","volume":"53","author":"Prince","year":"2004","journal-title":"Gut"},{"key":"R9-20240829","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1089-3261(03)00100-4","article-title":"Natural history of primary biliary cirrhosis","volume":"7","author":"Pares","year":"2003","journal-title":"Clin Liver Dis"},{"key":"R10-20240829","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1089-3261(03)00105-3","article-title":"Pruritus and fatigue in primary biliary cirrhosis","volume":"7","author":"Bergasa","year":"2003","journal-title":"Clin Liver Dis"},{"issue":"Suppl 1","key":"R11-20240829","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.4103\/sjg.sjg_112_21","article-title":"Cholestatic liver disease: Practice guidelines from the Saudi Association for the Study of Liver diseases and Transplantation","volume":"27","author":"Mawardi","year":"2021","journal-title":"Saudi J Gastroenterol"},{"key":"R12-20240829","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.autrev.2014.01.041","article-title":"The diagnosis of primary biliary cirrhosis","volume":"13","author":"Bowlus","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R13-20240829","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJMe1607744","article-title":"Primary biliary cholangitis--A New name and a new treatment","volume":"375","author":"Pratt","year":"2016","journal-title":"N Engl J Med"},{"key":"R14-20240829","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"R15-20240829","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/flgastro-2016-100741","article-title":"Primary biliary cholangitis: New treatments for an old disease","volume":"8","author":"Trivedi","year":"2017","journal-title":"Frontline Gastroenterol"},{"key":"R16-20240829","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A Placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"R17-20240829","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/00365521.2019.1606931","article-title":"Biochemical response to ursodeoxycholic acid among PBC patients: A nationwide population-based study","volume":"54","author":"Ornolfsson","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"R18-20240829","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1007\/s10620-019-06009-3","article-title":"Symptom burden and treatment response in patients with primary biliary cholangitis (PBC)","volume":"65","author":"Kaps","year":"2020","journal-title":"Dig Dis Sci"},{"key":"R19-20240829","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s00535-013-0903-1","article-title":"Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients","volume":"49","author":"Lammert","year":"2014","journal-title":"J Gastroenterol"},{"key":"R20-20240829","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/apt.12522","article-title":"Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study","volume":"38","author":"Papastergiou","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-20240829","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/MEG.0000000000000765","article-title":"Clinical significance of the Scheuer histological staging system for primary biliary cholangitis in Japanese patients","volume":"29","author":"Namisaki","year":"2017","journal-title":"Eur J Gastroenterol Hepat"},{"key":"R22-20240829","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"key":"R23-20240829","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_445_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:10:43Z","timestamp":1787166643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_445_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_445_21","relation":{},"ISSN":["1319-3767","1998-4049"],"issn-type":[{"value":"1319-3767","type":"print"},{"value":"1998-4049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]},"assertion":[{"value":"2021-09-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}